Amgen (AMGN) 174.16 $AMGN Amgen (AMGN) Breaks Through

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen (AMGN) 174.16 $AMGN

Amgen (AMGN) Breaks Through Resistance at $172.68
Comtex SmarTrend(R) - Mon Aug 01, 8:46AM CDT
Amgen (NASDAQ:AMGN) has opened bullishly above the pivot of $171.61 today and has reached the first level of resistance at $172.68. Investors may be interested in a cross of the next upside pivot targets of $173.34 and $175.07.
AMGN: 174.16 (+2.13)

Top 7 Research Reports for July 29, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 29, 12:44PM CDT
Top 7 Research Reports for July 29, 2016
MDLZ: 43.48 (-0.50), JPM: 63.80 (-0.17), TMO: 159.56 (+0.72), AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), TM: 111.23 (-0.37), ORCL: 41.15 (+0.11)

UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:15AM CDT
UCB (UCBJF) reported results for the first half of 2016.
BIIB: 301.83 (+11.90), AMGN: 174.16 (+2.13), NKTR: 17.76 (+0.47)

Company News for July 29, 2016
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:10AM CDT
Companies In The News are: CELG,MA,HOG,AMGN
HOG: 51.66 (-1.26), AMGN: 174.16 (+2.13), MA: 95.07 (-0.17), CELG: 114.69 (+2.50)

Next Support Level for Amgen (AMGN) is $166.09
Comtex SmarTrend(R) - Thu Jul 28, 9:12AM CDT
Amgen (NASDAQ:AMGN) has opened bearishly below the pivot of $169.74 today and has reached the first level of support at $168.38. Investors may be interested in a cross of the next downside pivot targets of $166.09 and $162.44.
AMGN: 174.16 (+2.13)

The Zacks Analyst Blog Highlights: Facebook, Amgen, Whole Foods and Groupon
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Facebook, Amgen, Whole Foods and Groupon
WFM: 30.41 (-0.07), FB: 124.31 (+0.37), AMGN: 174.16 (+2.13), GRPN: 4.99 (+0.17)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 7:02AM CDT
Amgen (AMGN) once again delivered a "beat and raise" quarter with growth products accounting for more than 50% of product sales.
BIIB: 301.83 (+11.90), INVA: 13.04 (+0.17), AMGN: 174.16 (+2.13), FMS: 45.65 (unch)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71)

Facebook (FB) Owns Q2 Earnings on Huge Beat, Plus GRPN, GPRO and More
Mark Vickery - Zacks Investment Research - Wed Jul 27, 4:47PM CDT
Facebook (FB) has been priced to near-perfection, and in Q2 2016, it has indeed delivered. And Groupon shoots to the moon after hours.
WFM: 30.41 (-0.07), GPRO: 12.94 (+0.30), FB: 124.31 (+0.37), AMGN: 174.16 (+2.13), GRPN: 4.99 (+0.17)

Amgen Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Jul 27, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include:
AMGN: 174.16 (+2.13)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Covered Call reports for Chipotle Mexican Grill, Starwood Hotels & Resorts Worldwide, JetBlue, Amgen and Whole Foods Market include trade ideas that offer returns of 20% or more!
PR Newswire - Wed Jul 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CMG, HOT, JBLU, and WFM.
WFM: 30.41 (-0.07), CMG: 414.08 (-9.91), AMGN: 174.16 (+2.13), JBLU: 18.20 (-0.13), HOT: 77.71 (-0.35)

5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:36AM CDT
How will drug stocks like AMGN, GSK, VRTX and others, scheduled to report on Jul 27, fare this earnings season?
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), VRTX: 98.20 (+1.20), MDCO: 39.03 (-0.08), AMGN: 174.16 (+2.13), GSK: 45.25 (+0.18), ANIK: 50.64 (+0.72)

AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 9:11AM CDT
Will Imbruvica and Humira help AbbVie (ABBV) deliver a positive earnings surprise in Q2?
JNJ: 125.40 (+0.17), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), BMY: 76.19 (+1.38)

Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:43AM CDT
Alexion Pharmaceuticals (ALXN), which is set to report second-quarter 2016 results on Jul 28, had delivered a negative earnings surprise of 4.40% last quarter.
UTHR: 125.08 (+4.07), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38)

Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)

ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 100.25 (+0.83), INCY: 90.00 (-0.21), AMGN: 174.16 (+2.13), ARIA: 9.71 (+0.20)

Biotech Earnings Battle: Gilead (GILD) vs. Amgen (AMGN)
Eric Dutram - Zacks Investment Research - Mon Jul 25, 2:49PM CDT
Amgen and Gilead Sciences are both reporting earnings this week. Which company is the better bet right now?
GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13)

Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:49PM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) Biologic License Application (BLA) for brodalumab is up for review by an FDA panel.
VRX: 20.89 (-1.41), AZN: 33.84 (-0.30), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 18

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 15

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 88

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 0

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 16

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 0

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
Ivanti's AI Push Rests on Data, Control and Results

Updated Category News Views 107

Enterprise AI has a nasty habit of sounding brilliant right up until it meets a messy fleet of laptops, phones, patches and permissions. Ivanti’s latest product push is aimed squarely at that unglamorous collision point: giving AI systems governed access to the operational data inside Ivanti Neurons, then keeping humans and pre-set permissions in charge of what happens...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 0

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading

Top 5 Most Recently Viewed Articles

Apple Inc. Faces Class Action Lawsuit Over Securities Fraud

Updated Category News Views 299

Overview of the Class Action Lawsuit Against Apple Inc. The renowned law firm of Kessler Topaz Meltzer & Check, LLP has announced a significant class action lawsuit filed against Apple Inc. The lawsuit, now underway in the United States District Court for the Northern District of California, is focused on claims of securities fraud that impact investors of Apple...

Continue Reading
Oslo Stock Market Experiences Decline Amidst Mixed Performances

Updated Category News Views 102

Oslo Stock Market Experiences Decline The recent trading session on the Oslo Stock Exchange closed with a notable decline, reflecting a complex mixture of performances across various sectors. Generally, the market is affected by fluctuations in key industries such as Media, Transport, and Diversified Financials. Sector Performance Analysis The Oslo OBX index, a critical...

Continue Reading
Doodle's Tender Offer Results: Lexibook Holds Strong Position

Updated Category News Views 210

Doodle's Tender Offer Results Overview In a strategic move within the shares market, the results from Doodle's recent tender offer on Lexibook have been announced. This development is particularly interesting for investors and stakeholders in the electronic leisure products sector. The outcome signifies a notable consolidation of shares following the initiation of...

Continue Reading
Riot Platforms Sees Bullish Signals as Options Trade Surge

Updated Category News Views 283

Riot Platforms Sees Bullish Signals in Options Trading Recent market activities suggest that investors with significant capital are betting on a positive future for Riot Platforms (NASDAQ: RIOT). This turn towards bullish behavior in the stock market highlights the enthusiasm among wealthier traders and institutional investors. The fascinating aspect of this situation is...

Continue Reading
Highlights from Coloplast A/S Annual Meeting and Future Outlook

Updated Category News Views 215

Coloplast A/S Annual General Meeting Insights Coloplast A/S recently hosted its Annual General Meeting, where significant resolutions were discussed and approved. As the company continues to innovate in healthcare, these decisions reflect their commitment to improving the lives of millions. Annual Report Approval One of the main highlights at the meeting was the approval...

Continue Reading